SNDL Announces Completion of Parallel Asset Acquisition and Positions for Nasdaq-Consolidated U.S. Medical Cannabis Operations

Impact · against what's priced in

SNDL's completion of the Parallel asset acquisition provides immediate scale and a path to consolidated US medical cannabis revenue on the Nasdaq. The massive reduction of legacy debt and the expansion to 249 stores provide a concrete fundamental catalyst for valuation growth.

SNDL+0.70

No priced-in read yet